Entry

D11701                      Drug

Name

Luspatercept (USAN/INN);
Luspatercept-aamt;
Reblozyl (TN)

Product

REBLOZYL (Celgene Corporation)

Formula

C3350H5070N906O1044S38

Exact mass

75910.0875

Mol weight

75958.0146

Sequence

ETRECIYYNA NWELERTNQS GLERCEGEQD KRLHCYASWR NSSGTIELVK KGCWDDDFNC
YDRQECVATE ENPQVYFCCC EGNFCNERFT HLPEAGGPEV TYEPPPTGGG THTCPPCPAP
ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(Disulfide bridge: 5-35, 25-53, 60-79, 66-78, 80-85, 114-114', 117-117', 149-209, 255-313, 5'-35', 25'-53', 60'-79', 66'-78', 80'-85', 149'-209', 255'-313')

Type

Peptide

Remark

ATC code:

B03XA06

Product:

D11701<US>

Efficacy

Anti-anemic, Erythroid maturation agent

Disease

beta Thalassemia [DS:H00228]

Comment

Treatment of anemia associated with ineffective erythropoiesis

Target

ACVR2B [HSA:93] [KO:K13596]

Pathway

hsa04060

Cytokine-cytokine receptor interaction

hsa04350

TGF-beta signaling pathway

hsa04550

Signaling pathways regulating pluripotency of stem cells

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
  B03 ANTIANEMIC PREPARATIONS
   B03X OTHER ANTIANEMIC PREPARATIONS
    B03XA Other antianemic preparations
     B03XA06 Luspatercept
      D11701  Luspatercept (USAN/INN) <US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
  Blood Products and Modifiers, Other
   Blood Products and Modifiers, Micellaneous
    Luspatercept
     D11701  Luspatercept (USAN/INN)
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor serine/threonine kinases (RSTK)
   TGFBR2 family
    ACVR2B
     D11701  Luspatercept (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11701
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D11701
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11701

Other DBs

CAS:	1373715-00-4

PubChem:

405226567